Deferred Tax Assets, Valuation Allowance of Larimar Therapeutics, Inc. from 31 Dec 2011 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Larimar Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2011 to 31 Dec 2024.
  • Larimar Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $173,028,000, a 22% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Larimar Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $173,028,000 +$31,258,000 +22% 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q4 2023 $141,770,000 +$10,939,000 +8.4% 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q4 2022 $130,831,000 +$6,815,000 +5.5% 31 Dec 2022 10-K 24 Mar 2025 2024 FY
Q4 2021 $124,016,000 +$8,697,000 +7.5% 31 Dec 2021 10-K 14 Mar 2024 2023 FY
Q4 2020 $115,319,000 +$103,584,000 +883% 31 Dec 2020 10-K 14 Mar 2023 2022 FY
Q4 2019 $11,735,000 +$6,435,000 +121% 31 Dec 2019 10-K 25 Mar 2022 2021 FY
Q4 2018 $5,300,000 -$82,381,000 -94% 31 Dec 2018 10-K 04 Mar 2021 2020 FY
Q4 2017 $87,681,000 -$10,039,000 -10% 31 Dec 2017 10-K 05 Mar 2020 2019 FY
Q4 2016 $97,720,000 +$23,179,000 +31% 31 Dec 2016 10-K 05 Mar 2020 2019 FY
Q4 2015 $74,541,000 +$32,143,000 +76% 31 Dec 2015 10-K 14 Mar 2019 2018 FY
Q4 2014 $42,398,000 +$14,567,000 +52% 31 Dec 2014 10-K 09 Mar 2018 2017 FY
Q4 2013 $27,831,000 +$5,602,000 +25% 31 Dec 2013 10-K 10 Mar 2017 2016 FY
Q4 2012 $22,229,000 +$3,485,000 +19% 31 Dec 2012 10-K 15 Mar 2016 2015 FY
Q4 2011 $18,744,000 31 Dec 2011 10-K 25 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.